Actavis ( ACT ) files an ANDA for a generic version of Acorda Therapeutics ' ( ACOR ) MS drug Ampyra ( dalfampridine ) Extended Release Tablets, 10 mg. The company intends to vigorously defend its IP rights and
June 26 (Reuters) - Acorda Therapeutics Inc said Actavis Plc plans to market a generic version of Acorda 's multiple sclerosis treatment, Ampyra.
Acorda Therapeutics ( ACOR ) prices its $300M aggregate principal amount of convertible senior notes due 2012. The notes will bear an interest rate of 1
17% . MCRS +17% . INSY +15% . SCTY +16% . FST +16% . GWPH +15% . Top 10 Losers: PRPH -10% . REI -10% . BODY -7% . LITB -7% . ORMP -7% . DOM -7% . EDN -7% . QKLS -6% . ACOR -6% . CSLT -6% . Post your comment!
Acorda Therapeutics ( ACOR +0.5% ) plans to offer $300M aggregate principal amount of convertible senior notes due 2021 pursuant to a shelf registration
this week. Fampyra, which is marketed in the United States under the trade name Ampyra by the firm's partner Acorda Therapeutics ACOR , is the first approved treatment to improve walking in patients with multiple sclerosis. Fampyra now marks
EDT) were flat, as patent expirations on older products countered strong manufacturing and royalty revenue from Ampyra, Acorda and Biogen-Idec's BIIB new oral MS drug. Tysabri's net new-patient adds actually fell in the fourth quarter, as compared
exploring the possible sale of this business. Royalties on Acorda 's ACOR recently approved multiple sclerosis drug Ampyra will be key to EDT's future growth, and Acorda 's second-quarter results in August will give us a